These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38361246)

  • 21. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
    Krishnan A; Schneider CV; Hadi Y; Mukherjee D; AlShehri B; Alqahtani SA
    Diabetologia; 2024 Mar; 67(3):483-493. PubMed ID: 38117293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
    Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
    Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice.
    Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2020 Jun; 19(1):74. PubMed ID: 32522260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.
    McCormick TA; Kramer J; Liles EG; Amos Q; Martin JP; Adams JL
    BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38719507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
    Herrera Comoglio R; Vidal Guitart X
    Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
    Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
    Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries.
    Wallner M; Biber ME; Stolfo D; Sinagra G; Benson L; Dahlström U; Gudbjörnsdottir S; Cosentino F; Mol PGM; Rosano GMC; Butler J; Metra M; Lund LH; Ferrannini G; Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul; 10(4):296-306. PubMed ID: 38632048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.
    Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2021 Nov; 20(1):222. PubMed ID: 34774054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.
    Dicker D; Sagy YW; Ramot N; Battat E; Greenland P; Arbel R; Lavie G; Reges O
    JAMA Netw Open; 2024 Jun; 7(6):e2415392. PubMed ID: 38848064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
    Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
    Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
    Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis.
    Zhang X; Shao F; Zhu L; Ze Y; Zhu D; Bi Y
    BMC Pharmacol Toxicol; 2018 Sep; 19(1):58. PubMed ID: 30223891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
    Ferreira JP; Saraiva F; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
    Diabetes Obes Metab; 2023 Jun; 25(6):1495-1502. PubMed ID: 36722252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.
    Villaschi A; Ferrante G; Cannata F; Pini D; Pagnesi M; Corrada E; Reimers B; Mehran R; Federici M; Savarese G; Metra M; Condorelli G; Stefanini GG; Chiarito M
    Clin Res Cardiol; 2024 Jun; 113(6):898-909. PubMed ID: 38252145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplantation.
    Sweiss H; Hall R; Zeilmann D; Escamilla J; Bhayana S; Patel R; Long C
    Prog Transplant; 2022 Dec; 32(4):357-362. PubMed ID: 36039519
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
    Pineda ED; Liao IC; Godley PJ; Michel JB; Rascati KL
    J Manag Care Spec Pharm; 2020 May; 26(5):610-618. PubMed ID: 32347181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
    Gerstein HC; Li Z; Ramasundarahettige C; Baek S; Branch KRH; Del Prato S; Lam CSP; Lopes RD; Pratley R; Rosenstock J; Sattar N
    Circulation; 2023 Mar; 147(13):1004-1013. PubMed ID: 36802715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.